PIN4 SYSTEMATIC REVIEW OF THE EFFICACY AND SAFETY OF IMIQUIMOD 5% CREAM FOR THE TREATMENT OF EXTERNAL GENITAL WARTS  by Walczak, J et al.
Paris Abstracts A417
replaces DM20 measuring percentage of patients with HbA1c less than 7; DM24 (new 
indicator) measuring percentage with HbA1c less than 8; DM25 replaces DM07 mea-
suring percentage with HbA1c less than 9. The analysis objective is to estimate likely 
achievement of these new indicators and assess impact on QOF points. METHODS: 
Underlying achievement of current clinical indicators, reported by NHS Information 
Centre, is 66.8% and 92.3%, with average points achievement of 98.3% (16.7 from 
17) and 97.9% (10.8 from 11) for DM20 and DM07 respectively. Mean HbA1c of 
6.9 (standard deviation 1.5; 1–2 years after entry to study) was taken from UKPDS 
56. 252 HbA1c values (average diabetes QOF register) were generated from this dis-
tribution and percentage achievement of current and proposed indicators was calcu-
lated. This simulation was repeated 8,294 times (number of QOF practices) and 
average achievement for each indicator was noted. RESULTS: Average achievement 
of current indicators using UKPDS 56 distribution was estimated at 65.5% and 98.1% 
for DM20 and DM07 respectively, comparing favourably with reported results. 
Average achievement of proposed QOF indicators was estimated at 52.7%, 76.8% 
and 91.9% with maximum points (35 in total) awarded at 50%, 70% and 90% for 
DM23, DM24 and DM25 respectively. CONCLUSIONS: Although the QOF targets 
for HbA1c are lower, the average percentage achievement is estimated to reach the 
level required for maximum QOF points. However, since the average is close to the 
maximum payment level for DM23 and DM25 a number of practices are unlikely to 
reach this unless increased reductions in HbA1c are achieved.
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OBJECTIVES: Understanding current and new paths of treatment (POT) in diabetes 
is pivotal for estimating budget impacts when new antidiabetic agents are introduced 
to pharmacy formularies. Although diabetes treatment guidelines exist to guide pre-
scribers, very limited real-life data are available to illuminate actual POT’s for patients 
initiating insulin treatment. The aim of this study was to establish the most prevalent 
POT’s for insulin initiation using real-world US pharmacy data. METHODS: Medic-
aid, Cash and 3rd party payer pharmacy claims were obtained from SDI. A patient’s 
ﬁrst insulin Rx between October and December. 2004 served as an index Rx. A 6 
month look-back identiﬁed prior treatments and a 3 year look-forward tracked 
changes from the index Rx. To be eligible for analysis, patients had to have no insulin 
Rx in the look-back and be in the SDI database in the ﬁrst and last quarter of observa-
tion. The pattern of payers and prescribers were identiﬁed along with the most fre-
quent Rx combinations for each step. The average duration for each step was analyzed. 
RESULTS: Out of 351,887 patients with an index insulin Rx, 78,213 had no insulin 
in the look-back. Claims were paid by Medicaid (13%), cash (4%), and 3rd party 
(83%). The top-10 combinations prior to the index insulin constituted 96% of the 
data. The top 3 were Metformin(MET)  Sulfonylurea(SU) (18%), Met alone (17%) 
and SU alone (13%). The top-10 combinations initiating index insulin constituted 
59% of the data. The top 3 were MET  SU  basal insulin (11%), MET  SU  TZD 
 basal insulin (11%), and SU  basal insulin (6%). On average, patients initiating 
insulin went 230 days without changing their therapy. CONCLUSIONS: Based on 
real-world US data, a small number of therapy combinations explain the POT’s before 
insulin initiation. Upon initiating insulin treatment, combinations are more varied, 
although most include basal insulin.
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OBJECTIVES: Enfuvirtide is part of a novel class of agents known as fusion inhibitors 
approved following the phase III TORO trials. The objective of ZOOM cohort was 
to assess in real life setting long term efﬁcacy and safety of enfuvirtide in HIV-1 
patients. METHODS: ZOOM is a multicenter, observational, longitudinal, prospec-
tive French study conducted from September 2004 to September 2006. The main 
objectives were immuno-virological and clinical assessments during the treatment and 
after a 2 year follow-up. Secondary objectives were patient’s characteristics, drug 
treatment modalities, safety and quality of life. RESULTS: During this period, 364 
patients were included, their characteristics were as follow: mean age : 45 o 9 years, 
median viral load: 4,70 log10 copies/ml, median CD4 count : 155 cell/mm3; AIDS 
deﬁning events : 52%; antiretroviral pre-treated patients: 97% since a mean of 10 o 
3 years. These characteristics were similar to the HIV French Hospital database. At 
24 months, 43% of treated patients had an undetectable HIV plasma viral load 
(threshold 400 copies/mL) and 39% had a CD4 increase of at least 100 cell/ mm3 
(versus 27% and 32% respectively in the TORO trial). The most common adverse 
event was injection site reaction (93% versus 98% in TORO). In addition, the prob-
ability at 12 months of an AIDS deﬁning events or patient death was 12% (IC95% 
 [9%; 16%]). CONCLUSIONS: The ZOOM observational study conﬁrmed, in real 
life setting, enfuvirtide safety and efﬁcacy demonstrated in the TORO trials. It also 
shows that enfuvirtide drug treatment modalities follow the summary of product 
characteristics recommendations.
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OBJECTIVES: Hepatic impairment from chronic hepatitis C (CHC) has signiﬁcant 
implications for drugs that are extensively cleared by liver, presenting extra challenges 
to manage comorbidities for CHC patients. This study is to assess the comorbidity 
burden of hepatitis C virus (HCV) infection in Europe to better understand the needs 
for proper disease management of patients with CHC. METHODS: National Health 
and Wellness Survey (NHWS) is an annual cross-sectional survey from representative 
adults, including information regarding health care attitudes, behaviors, demographic 
and disease characteristics, resource utilization, and health-related outcomes. In this 
study, NHWS data obtained from France, Germany, Italy, Spain, and UK in 2006–
2008 were analyzed and self-reported CHC were categorized as cases. Propensity-
matched non-CHC survey responders were selected as controls based on country, 
gender, age, education, employment, and year of survey. Conditional logistic regres-
sion was applied controlling for HIV, marital status, smoking status, alcohol consump-
tion and body mass index. RESULTS: The ﬁnal sample included 864 cases and 864 
closely matched controls: 61% were male with mean age of 49.8. After adjusting for 
HIV status, the most prevalent conditions ever experienced by CHC patients included 
hypertension (27%), high cholesterol (17%), diabetes (12%), chronic bronchitis 
(11%), arthritis (10%), hepatitis B (10%), thyroid disorders (10%), cancer (9%), and 
ulcer (gastric or duodenal—9%). Compared to the control adjusting for HIV status 
and other covariates, CHC patients were associated with signiﬁcantly higher risks for 
32 medical conditions collected in the survey. CONCLUSIONS: CHC patients have 
a high burden of comorbidities, many of which require long-term or intensive phar-
macological management. This could suggest that treating HCV infection early to 
prevent the deterioration in liver function is essential for the management of comorbid 
conditions, and should be among the key goals of comprehensive CHC management 
strategies.
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OBJECTIVES: LPV/r SAT may durably suppress HIV and maintain immunologic 
response in multiple trial settings, but criteria for improved clinical outcomes have 
not been determined. Our objective was to evaluate LPV/r SAT use and predictors of 
viral suppression in an urban clinic setting. METHODS: A retrospective, longitudinal 
cohort study was conducted of all patients q18 years old with q2 HIV-1 RNA (“viral 
load”, VL) measurements starting LPV/r SAT from 2003–2007 at a large urban HIV 
clinic. Exclusion criteria: prospective clinical trial enrollment or missing data. Vari-
ables (demographics, baseline plasma VL and CD4, previous HAART, adherence, and 
missed clinic visits) evaluated by univariate and stepwise logistic regression to deter-
mine predictors of virologic suppression (achievement and/or maintenance of VL  
50copies/mL). RESULTS: Ninety-one patients met inclusion criteria (73% male; 54% 
black, 35% Caucasian, and 11% Hispanic). Mean age was 42.4 years, median CD4 
prior to SAT 290 cells/mm3, and median VL 8960 copies/mL. Reasons for SAT (pro-
vider and patient perspective): easy regimen (29%), simpliﬁcation/maintenance (26%), 
antiretroviral toxicity (21%), and adherence (23%). In patients with q6 months 
follow-up (n  82), 37 were HAART-naïve and 45 had q1 previous HAART regimen. 
Overall, 73% of HAART-naïve and 47% of patients with q1 previous HAART 
regimen achieved/maintained viral suppression. In univariate analyses, age, adherence, 
ethnicity, low VL, high CD4, and AIDS status were signiﬁcant predictors (p  0.05). 
Regression analysis indicated age  50 years (OR 5.2 [95% CI, 1.1–18.4]), white 
ethnicity (OR 2.5 [1.1–8.3]), and no AIDS (OR 3.0 [1.2–12.5]) were independently 
associated with viral suppression (p  0.05). SAT was stopped in 17/91 patients for 
viral failure, poor adherence, drug toxicity, or drug cost. CONCLUSIONS: Incidence 
of viral suppression was similar to prospective controlled trials in HAART-naive 
patients. Older patients with no/mild immunosuppression and limited prior antiretro-
viral experience may be better candidates for LPV/r SAT. Larger, prospective evalua-
tions are needed.
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OBJECTIVES: The main goal of the review was to compare clinical effectiveness 
of imiquimod 5% cream versus vehicle or conventional ablative methods for the 
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treatment of external genital warts. METHODS: The analysis was performed in 
accordance with the rules of systematic review, based on the Cochrane Collaboration 
(Cochrane Reviewer’s Handbook) guidelines and the Health Technology Assessment 
Agency in Poland (AOTM) recommendations. RESULTS: Imiquimod ﬁve percent 
cream versus vehicle in short time period: Treatment with imiquimod resulted in sig-
niﬁcantly higher probability of achieving complete clearance of the genital warts than 
for vehicle group. The most frequently adverse events were erythema and erosion. 
Imiquimod ﬁve percent cream versus vehicle in long time period: Treatment with 
imiquimod resulted in signiﬁcantly greater number of patient who achieved total wart 
clearance and 50% or greater reduction in total wart area in comparison with control. 
The chance of experiencing local inﬂammatory reaction at the wart site such as ery-
thema and erosion was signiﬁcantly higher in experimental group than control. Imiqui-
mod ﬁve percent cream versus vehicle in HIV-infected patients: Imiquimod was 
signiﬁcantly more effective than vehicle in the topical treatment of external anogenital 
warts in HIV–seropositive patients. Imiquimod patients more frequently experienced 
at least 50% reduction in baseline wart area. The most common local skin reaction 
was erythema. Imiquimod 5% cream versus conventional ablative methods : Imiqui-
mod 5% therapy is related with a higher chance of achieved complete clearance of 
warts as well as higher probability of sustained clearance. Probability of recurrence 
anogenital warts during treatment was signiﬁcantly higher in control than intervention 
group. The most frequently reported local skin reactions were erythema and erosion. 
CONCLUSIONS: Imiquimod appears to have a signiﬁcant therapeutic effect in the 
treatment of external genital warts. Although local skin reactions were more frequently 
during the imiquimod treatment, they subsided spontaneously in most cases.
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OBJECTIVES: To assess and compare epidemiological characteristics and resource 
use of varicella in the Dutch-GP setting, by obtaining data about the incidence of 
complications and medication use. METHODS: We performed a retrospective popula-
tion-based cohort study (2004–2008) in the Zorggroep Almere database, a GPs’ 
research database with longitudinal data from electronic patient records of 164,631 
patients (in 2004) in Almere. New cases were included each year. Patient records were 
reviewed to evaluate varicella incidence, complications and medication use. The iden-
tiﬁcation of varicella incidence and related complications was not only performed via 
ICPC-diagnoses, also free text ﬁelds were analyzed on relevance. Hospital referrals 
were used to evaluate referral rates. RESULTS: The average of the absolute annual 
incidence of GP-consultations in The Netherlands, corrected for age distribution of 
the population, was 49.7 per 10,000 overall; 465.5 for 0–1 year-olds; 573.7 for 1–4 
year-olds; 153.5 for 5–9 year-olds; 8.3 for 9-year-olds. Of the patients 1.7% had 
neurological, 6.1% cutaneous, 22.6% pulmonary and 24.2% any other complication. 
Forty-seven percent of all patients received medication; most frequently skin products 
(63.8%). Referral rate was 1.5%; 66.7% to pediatric departments. When only ICPC-
diagnoses were used, the absolute incidence of GP-consultations was 37.7 per 10,000 
(1.6% of the cases were false-positive). Comparing our overall incidence (49.7 per 
10,000) with data (2004–2007) of a national registry of GP-data (23.8 per 10,000) 
shows an underestimation on the overall incidence of 25.9 per 10,000. CONCLU-
SIONS: The epidemiology of complications shows a high resource use due to varicella 
infections and a high incidence of GP-consultations in 1–4 year-olds. When estimating 
incidence of varicella in primary care, based on national diagnostic codes only, one 
should be aware of a gross (100%) underestimation of the incidence. Our analysis 
may have important implications for the outcomes of upcoming cost-effectiveness 
analyses on varicella vaccination in the Dutch setting.
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OBJECTIVES: To evaluate the effect of bloodstream infections (BSI) on outcome and 
resources use among patients with severe burn injuries. METHODS: A retrospective 
(period 1992 to 2006), pairwise-matched (matching ratio 1:1 to 1:2 if feasible), risk-
adjusted cohort study was conducted at the 6-bed burn unit of a university hospital 
in Belgium. Burn patients with a microbiologically documented BSI (cases, n  76) 
and control subjects (n  108) matched on basis of burn severity (identical Belgian 
Outcome in Burn Injury [BOBI] score) and length of hospitalization (equivalent or 
longer) before the onset of BSI in the index case patient. RESULTS: Predominant 
pathogens were Staphylococcus aureus, enterococci, Pseudomonas aeruginosa, 
Escherichia coli, coagulase-negative staphylococci, and Candida spp. Median age was 
42 years (interquartile range [IQR] 31–52). Median total burned surface area was 
40% (IQR: 25–50%). Forty-one patients experienced an inhalation injury (53.9%). 
The median BOBI score was 4 (IQR: 2–5). The median ICU length of stay before onset 
of BSI was 11 days (IQR: 5.3–19.8 days). Adequate antibiotic treatment was admin-
istered in 76.3% of the cases within the ﬁrst 48 hours after onset of infection. Com-
pared to matched control subjects, patients with BSI had a signiﬁcant higher need for 
vasopressive/inotropic support (57.9% vs. 39.8%, p  0.017), whereas need for ven-
tilatory assistance and renal replacement therapy were not signiﬁcantly higher among 
cases. Hospital mortality did not differ between cases and control subjects (11.8% vs. 
17.5%, p  0.298). However, BSI was associated with an excess length of hospitaliza-
tion of 25 days (61 vs. 36 days; p  0.001), and an excess length of mechanical ventila-
tion of 11 days (21 vs. 10 days; p  0.001). CONCLUSIONS: In this cohort of severe 
burn injury patients, BSI did not adversely affect outcome, but contributed to a sub-
stantial economic burden through excess length of mechanical ventilation and length 
of hospital stay.
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OBJECTIVES: Doripenem, a new carbapenem, has been approved for nosocomial 
pneumonia (NP) including ventilator-associated pneumonia (VAP), complicated intra-
abdominal infections and complicated urinary tract infections in Europe. This study 
aimed at estimating the budgetary impact of adding doripenem to a hospital formulary 
for treatment of NP and VAP in Germany. METHODS: An Excel-based model was 
developed in accordance with Good Research Practices for Budget Impact Analysis 
disseminated by the ISPOR to estimate the annual impact on a hospital’s budget of 
adding doripenem. Model inputs included annual hospital admissions for NP and 
VAP, current share of imipenem and meropenem use (50% each, no doripenem use), 
treatment duration and length of stay (LOS) from clinical trials and assumptions, 
hospitalization costs from published literature and Federal Health Monitoring, list 
prices for doripenem from the online pharmaceutical database Lauer-Taxe and dis-
counted prices for imipenem and meropenem from IMS GPI Krankenhaus-Index. All 
costs were in 2008 Euros. A new proportional share of 50% doripenem, 30% imipe-
nem and 20% meropenem was assumed for this analysis. Sensitivity analyses explored 
the impact on results of different proportions of doripenem use. RESULTS: The total 
cost per treated patient (based on NP/VAP pooled population) prior to the introduc-
tion of doripenem was estimated to be a12,513. With the new proportional share, 
total cost was estimated to decrease to a11,896, a 5% reduction in the hospital budget. 
Addition of doripenem led to a a617 savings per patient primarily due to a reduction 
in hospital days and days on mechanical ventilation. Increasing the proportion of 
doripenem use resulted in larger savings to the hospital budget (a1217 per patient at 
100% doripenem use). CONCLUSIONS: Results indicate that adding doripenem to 
a hospital formulary for treatment of NP and VAP will yield potential savings to a 
hospital’s budget in Germany.
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OBJECTIVES: To estimate the expected impact of the newly licensed 10-valent pneu-
mococcal non-typeable Haemophilus inﬂuenzae protein-D conjugate vaccine (PHiD-
CV) on health care budgets in Canada. METHODS: The budget impact analysis (BIA) 
uses the previously published PHiD-CV population model. The BIA compares a PCV-
7-primed condition at vaccine steady state with the introduction of PHiD-CV within 
the Canadian market assuming a gradual annual uptake of 20% over 5 years (2009–
2013). The market share assumptions are based on 100% vaccination coverage in a 
4-dose (3  1) schedule. The population modeled is the entire population of Canada 
(33.0 million). The vaccinated cohort is 348,000. Analysis was performed from the 
Canadian health care system perspective assuming a price parity of $70 per dose. The 
model includes the direct medical costs related to the management of invasive pneu-
mococcal diseases, community acquired pneumonia and acute otitis media (AOM) 
obtained from published Canadian studies. Various sensitivity analyses were per-
formed to assess the robustness of the key model assumptions. RESULTS: Assuming 
a 20% market share in Year 1 (2009), the introduction of PHiD-CV will result in a 
cost-savings of $4.7 million, compared with PCV-7 at price parity. In 2013 (Year 5), 
with PHiD-CV market share increasing to 100%, the expected annual direct cost 
savings is estimated to grow to $23.6 million, resulting in cumulative cost savings of 
$70.9 million over 5 years. Approximately 70% of the projected savings is due to the 
superior AOM protection offered by PHiD-CV vaccination. Sensitivity analyses show 
that change in vaccination price, dosing strategy, and vaccine coverage have the biggest 
impact on projected cost-savings. CONCLUSIONS: The results suggest that the Cana-
dian health care system can realize substantial cost savings by substituting PCV-7 with 
PHiD-CV in routine infant pneumococcal vaccination programs. With 100% substitu-
tion, annual direct cost savings is projected to be $67.9 per child vaccinated.
